Biljana Belamarić Wilsey
Principal R&D Program Manager, SAS
Biljana Belamarić Wilsey, PhD, is a Principal R&D Program Manager at SAS. A SAS employee for 10 years, Biljana has spent the past 5 years innovating, testing, and maintaining NLP, with a focus on text analytics, information extraction, categorization, and political discourse. In 2018, she received the prestigious SAS CEO Award of Excellence.
By This Author
SAS® Text Analytics for Business Applications: Concept Rules for Information Extraction Models
By Teresa Jade, Biljana Belamarić Wilsey, and Michael D. Wallis
Information extraction is the task of automatically extracting structured information from unstructured or semi-structured text. SAS® Text Analytics for Business Applications: Concept Rules for Information Extraction Models focuses on this key element of natural language processing and provides real-world guidance on the effective application of text analytics.
insideBIGDATA: What a Holiday Tweet and a Faulty Fridge Can Tell Us
SAS Voices article: Text analytics through linguists’ eyes: When is a period not a full stop?
Featured Authors
-
Terisa Roberts is a director and Global Solution lead for Risk Modeling and Decisioning at SAS. She has extensive experience in quantitative risk management, regulatory compliance, and model governance and validation. She has worked in financial services, telecommunications, government, energy, and retail sectors.
-
Robert N. Rodriguez retired from SAS in 2018 after serving as a senior director in research and development. Bob received a PhD in statistics from the University of North Carolina at Chapel Hill and was a research statistician at General Motors Research Laboratories before joining SAS.
-
Ron Klimberg, PhD, is a professor at the Haub School of Business at Saint Joseph's University in Philadelphia, PA.
-
Todd Case has been working in the pharmaceutical industry as a statistical programmer for over 20 years. He completed his MS in Epidemiology from Columbia University and has worked at Forest Laboratories (now Allergan), Genentech, Bristol-Myers Squibb, and Biogen. He currently works at Vertex Pharmaceuticals.